Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

News Conference News AHA 2024

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

Yael L. Maxwell

November 16, 2024

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

November 13, 2023

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

November 09, 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

News Conference News AHA 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

November 08, 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

November 05, 2022

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

November 08, 2021

One Pill to Treat Them All: Polycap Strategy Sees Success in TIPS-3

News Conference News AHA 2020

One Pill to Treat Them All: Polycap Strategy Sees Success in TIPS-3

Michael O'Riordan

November 13, 2020

Long-Awaited Hypertension Guidelines Released at AHA

News Conference News AHA 2017

Long-Awaited Hypertension Guidelines Released at AHA

November 13, 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.